Centre Hospitalier Sud Essonne-Dourdan-Etampes
- Address
- 26 Avenue Charles De Gaulle, 91150 Étampes, France
Centre Hospitalier Sud Essonne-Dourdan-Etampes
The Centre Hospitalier Sud Essonne-Dourdan-Etampes is a specialized research institution with significant expertise in critical care medicine and intensive care unit (ICU) interventions. The center demonstrates particular strength in investigating sepsis and septic shock management, focusing on innovative therapeutic approaches to reduce organ dysfunction and improve patient outcomes in critically ill populations.
- Corticosteroid therapy optimization in septic shock and critical illness-related corticosteroid insufficiency (CIRCI)
- Novel interventions for sepsis-related complications, including ARDS management with high-dose vitamin C therapy
- Neurological complications in ICU settings, specifically delirium prevention and treatment during septic shock
- Pediatric infectious disease management, including acute osteomyelitis treatment strategies
The research center conducts rigorous randomized, double-blind, placebo-controlled trials examining multiple aspects of critical care management. Their investigations span from adult ICU populations with life-threatening conditions to pediatric patients with acute infections, consistently evaluating composite outcomes including mortality, organ dysfunction, and mechanical ventilation dependency. The center's work on precision medicine approaches includes identifying biological profiles for immune responses and corticosteroid bioactivity to optimize treatment strategies for individual patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Sud Essonne-Dourdan-Etampes
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Beta-lactam Intermittent vs. Continuous Infusion and Combination Antibiotic Therapy in ICU Patients with Hospital-acquired Sepsis | Assistance Publique Hopitaux De Paris | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fludrocortisone Acetate | 2 | Unknown | 2022-02-17 | 2026-07-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.